With over 18 years of experience in the medical field. siParadigm has built a legacy in laboratory testing solutions based on scientific excellence, innovation, and world-class service. siParadigm has earned national accreditation from CLIA and CAP, as well as local licensing in several states. Our test menu achieves maximum coverage for potentially actionable aberrations such as: Single Nucleotide Variants (SNVs) , Insertions & Deletions (InDels), Copy Number Variants (CNVs), Gene Fusions (RNA), Splice Variants (RNA), Somatic and germline Homologous Recombination Deficiency (HRD) and Loss of Heterogeneity (LOH) for Specific genomic signatures: Tumor Mutation Burden (TMB) and Microsatellite Instability (MSI). Our testing methodologies encompasses all major technologies for tissue-based and liquid biopsy testing of solid tumor and hematologic cancers as: IHC, Targeted or Broad-Panel DNA- and RNA-based, FISH, Cytogenetics, Flow Cytometry and Next Generation Sequencing (NGS). At siParadigm, our priority is accuracy, integrity, and quality for our clients. Our experienced team of professionals uses advanced technology to provide prompt results to ensure accuracy. We also have a strong commitment to quality in order to guarantee the best results for you.